Table 2.
The interaction between m6A and ncRNA in cancer therapeutic resistance.
| M6A regulators | NcRNAs | Functions | Therapeutic responses | Cancers | Refs |
|---|---|---|---|---|---|
| METTL3 | MiR-221-3p | Stimulating pri-miR-221-3p maturation | Sustaining doxorubicin resistance | Breast cancer | 164 |
| METTL3 | MiR-4443 | Interfering METTL3-mediated FSP1 m6A methylation | Conferring cisplatin resistance | Lung cancer | 165 |
| METTL3 | LncRNA MALAT1 | Enhancing MALAT1 stability | Conferring cisplatin resistance | Lung cancer | 63 |
| METTL3 | LOC554202 | Promoting FOXO3 methylation and its downstream LOC554202 | Inhibiting sorafenib resistance | Hepatocellular carcinoma | 166 |
| METTL3 | LINC00922 | Enhancing TFAP2C stability and promoting LINC00922 transcription | Promoting doxorubicin resistance | Osteosarcoma | 168,169 |
| METTL3 | LncRNA ARHGAP5-AS1 | Increasing M3TTL3-mediated ARHGAP5 stabilization | Conferring cisplatin resistance | Gastric cancer | 97 |
| METTL3 | CircCUX1 | Enhancing circCUX1 stability | Reversing radiotherapy resistance | Hypopharyngeal squamous cell carcinoma | 170 |
| METTL3 | CircRNA-SORE | Increasing m6A level of circRNA-SORE | Promoting sorafenib resistance | Hepatocellular carcinoma | 171 |
| ALKBH5 | Circ_0072083 | Increasing ALKBH5 expression | Promoting temozolomide resistance | Glioma | 173 |
| FTO | LncRNA HLA-F-AS1 | Activation STAT3 and inducing HLA-F-AS1 expression | Facilitating doxorubicin resistance | Breast cancer | 174,175 |
| HNRNPA2/B1 | Results in a significant change in multiple miRNAs | Promoting tamoxifen resistance | Breast cancer | 60 |